DNA viruses (CMV, EBV, and the herpesviruses)

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 4, 2011, Pages 454-470

  Zamora, Martin R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytomegalovirus; Epstein Barr virus; ganciclovir; herpes simplex virus; organ transplant; valganciclovir; varicella zoster virus

Indexed keywords

ACICLOVIR; BLEOMYCIN; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE;

ALLOGRAFT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; COST CONTROL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENOTYPE; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNOGLOBULIN DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NONHUMAN; PATIENT MONITORING; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SEROPREVALENCE; T CELL LYMPHOMA; VARICELLA ZOSTER VIRUS; VIRUS ISOLATION; VIRUS LOAD; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 80051990656     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1283285     Document Type: Article

References (145)

1. Shah P D., McDyer J F. Viral infections in lung transplant recipients. Semin Respir Crit Care Med 2010 31 2 243-254
2. Costa C, Delsedime L, Solidoro P et al. Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc 2010 42 4 1270-1274
3. Fishman J A., Rubin R H. Infection in organ-transplant recipients. N Engl J Med 1998 338 24 1741-1751 (Pubitemid 28268592)
4. Paya C V., Razonable R R. Cytomegalovirus infection after solid organ transplantation. In: Bowden R A. Ljungman P Paya C V. eds. Transplant Infections. 2nd ed. Philadelphia, PA Lippincott, Williams and Wilkens 2003
5. Zamora M R. Cytomegalovirus and lung transplantation. Am J Transplant 2004 4 8 1219-1226 (Pubitemid 39013567)
6. Zamora M R. Viral infections complicating lung and solid organ transplantation. In: Lynch III J P. Ross D J. eds. Lung and HeartLung Transplantation. New York Taylor and Francis 2006 485-525
7. Mitsani D, Nguyen M H., Kwak E J. et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant 2010 29 9 1014-1020
8. Dunn H S., Haney D J., Ghanekar S A., Stepick-Biek P, Lewis D B., Maecker H T. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002 186 1 15-22 (Pubitemid 34666909)
9. Zamora M R., Davis R D., Leonard C, CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005 80 2 157-163 (Pubitemid 41061670)
10. Kotton C N., Kumar D, Caliendo A M. et al, Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010 89 7 779-795
11. Valantine H A. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Transplant Proc 1995 27 5, Suppl 1 49-57
12. Balthesen M, Messerle M, Reddehase M J. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993 67 9 5360-5366 (Pubitemid 23241369)
13. Mendez J C., Dockrell D H., Espy M J. et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001 183 2 179-184 (Pubitemid 32066016)
14. Jamil B, Nicholls K M., Becker G J., Walker R G. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant 2000 14 1 14-18 (Pubitemid 30079525)
15. van der Meer J T., Drew W L., Bowden R A. et al. Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis and cytomegalovirus infection. Antiviral Res 1996 32 3 119-140 (Pubitemid 26395492)
16. Duncan S R., Paradis I L., Yousem S A. et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992 146 6 1419-1425
17. Snyder L D., Finlen-Copeland C A., Turbyfill W J., Howell D, Willner D A., Palmer S M. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010 181 12 1391-1396
18. Snydman D R. Infection in solid organ transplantation. Transpl Infect Dis 1999 1 1 21-28
19. Singh N, Arnow P M., Bonham A et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997 64 5 716-720 (Pubitemid 27407098)
20. McCarthy J M., Karim M A., Krueger H, Keown P A. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993 55 6 1277-1282 (Pubitemid 23183237)
21. Falagas M E., Arbo M, Ruthazer R et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997 63 11 1595-1601 (Pubitemid 27265500)
22. Kim W R., Badley A D., Wiesner R H. et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000 69 3 357-361 (Pubitemid 30118114)
23. Tolkoff-Rubin N E., Fishman J A., Rubin R H. The bidirectional relationship between cytomegalovirus and allograft injury. Transplant Proc 2001 33 1-2 1773-1775 (Pubitemid 32238059)
24. Beck S, Barrell B G. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988 331 6153 269-272 (Pubitemid 18040595)
25. Winston D J., Antin J H., Wolff S N. et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001 28 2 187-196 (Pubitemid 32725720)
26. Duncan S R., Grgurich W F., Iacono A T. et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994 150 1 146-152 (Pubitemid 24209951)
27. Schulman L L., Weinberg A D., McGregor C C., Suciu-Foca N M., Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001 163 2 437-442 (Pubitemid 32158525)
28. Ettinger N A., Bailey T C., Trulock E P. et al, Washington University Lung Transplant Group. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993 147 4 1017-1023 (Pubitemid 23093832)
29. Sharples L D., Tamm M, McNeil K, Higenbottam T W., Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantationearly risk factors. Transplantation 1996 61 4 560-566
30. Weseslindtner L, Nachbagauer R, Kundi M et al. Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response. Am J Transplant 2011 11 3 542-552
31. Bowden R A., Slichter S J., Sayers M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995 86 9 3598-3603
32. Palmer S M., Limaye A P., Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010 152 12 761-769
33. Baldanti F, Revello M G., Percivalle E, Gerna G. Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised. J Clin Virol 1998 11 1 51-60 (Pubitemid 28462073)
34. Egan J J., Barber L, Lomax J et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995 50 1 9-13
35. Bewig B, Haacke T C., Tiroke A et al. Detection of CMV pneumonitis after lung transplantation using PCR of DNA from bronchoalveolar lavage cells. Respiration 2000 67 2 166-172 (Pubitemid 30193089)
36. Michaelides A, Liolios L, Glare E M. et al. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonitis. Transplantation 2001 72 1 141-147 (Pubitemid 32652520)
37. Guiver M, Fox A J., Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 2001 71 11 1609-1615 (Pubitemid 32574163)
38. Masaoka T, Hiraoka A, Ohta K et al. Evaluation of the AMPLICOR CMV, COBAS AMPLICOR CMV monitor and antigenemia assay for cytomegalovirus disease. Jpn J Infect Dis 2001 54 1 12-16 (Pubitemid 32499510)
39. Mazzulli T, Drew L W., Yen-Lieberman B et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999 37 4 958-963 (Pubitemid 29140597)
40. Bhorade S M., Sandesara C, Garrity E R. et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001 20 9 928-934 (Pubitemid 32824137)
41. Humar A, Paya C, Pescovitz M D. et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/Rsolid organ transplant recipients. Am J Transplant 2004 4 4 644-649 (Pubitemid 38523588)
42. Chemaly R F., Yen-Lieberman B, Castilla E A. et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 2004 42 5 2168-2172 (Pubitemid 38637838)
43. Humar A, Gregson D, Caliendo A M. et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999 68 9 1305-1311
44. Weinberg A, Hodges T N., Li S, Cai G, Zamora M R. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000 38 2 768-772 (Pubitemid 30082679)
45. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother 1989 23 Suppl E 49-60 (Pubitemid 19182022)
46. Soghikian M V., Valentine V G., Berry G J., Patel H R., Robbins R C., Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996 15 9 881-887 (Pubitemid 26320212)
47. Duncan S R., Paradis I L., Dauber J H., Yousem S A., Hardesty R L., Griffith B P. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992 146 5 Pt 1 1213-1215
48. Kelly J L., Albert R K., Wood D E., Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995 59 8 1144-1147
49. Hertz M I., Jordan C, Savik S K. et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998 17 9 913-920 (Pubitemid 28440855)
50. Limaye A P., Raghu G, Koelle D M., Ferrenberg J, Huang M L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002 185 1 20-27 (Pubitemid 34043012)
51. Paya C V. A randomized, double-blinded, double-dummy, active comparator controlled multicenter study of the efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of CMV in 372 high-risk (D+/R-) heart, liver and kidney recipients. [Abstract LB-4] In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2730, 2002, San Diego, California. American Society for Microbiology Press, 2002.
52. Maurer J R., Snell G, deHoyos A, Kesten S, Winton T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc 1993 25 1 Pt 2 1434-1435 (Pubitemid 23079051)
53. Gould F K., Freeman R, Taylor C E., Ashcroft T, Dark J H., Corris P A. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant 1993 12 4 695-699 (Pubitemid 23227096)
54. Kruger R M., Paranjothi S, Storch G A., Lynch J P., Trulock E P. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003 22 7 754-763 (Pubitemid 36842927)
55. Bailey T C., Trulock E P., Ettinger N A., Storch G A., Cooper J D., Powderly W G. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992 165 3 548-552
56. Zamora M R. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001 3 Suppl 2 49-56 (Pubitemid 34073657)
57. Valantine H A., Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001 72 10 1647-1652
58. Poirier C D., Doyle R L., Theodore J et al. Comparison between CMV Hyperimmune globulin and GCV for CMV prophylaxis in heart-lung and lung transplant recipients. J Heart Lung Transplant 1998 17 96
59. Weill D, Lock B J., Wewers D L. et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003 3 4 492-496 (Pubitemid 36560103)
60. Zamora M R., Nicolls M R., Hodges T N. et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 10 1635-1642 (Pubitemid 39312297)
61. Kelly J, Hurley D, Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000 19 4 355-359 (Pubitemid 30211658)
62. Weill D, Zamora M R. Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000 19 8 815-816
63. Zuk D M., Humar A, Weinkauf J G., Lien D C., Nador R G., Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010 90 6 672-676
64. Asberg A, Humar A, Jardine A G. et al, VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009 9 5 1205-1213
65. Rubin R H., Lynch P, Pasternack M S., Schoenfeld D, Medearis D N. Jr. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother 1989 33 11 1975-1979 (Pubitemid 19266264)
66. Goldfarb N S., Avery R K., Goormastic M et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001 71 2 242-246 (Pubitemid 32126107)
67. Yamani M H., Avery R K., Mawhorter S D. et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant 2001 20 4 425-430 (Pubitemid 32303144)
68. Rubin R H. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000 19 8 731-735
69. Turgeon N, Fishman J A., Doran M et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000 2 1 2-10 (Pubitemid 30139958)
70. Nankivell B J., Malouf M A., Russ G R. et al. Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection. Clin Transplant 1998 12 3 270-273 (Pubitemid 28269253)
71. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999 12 2 286-297 (Pubitemid 29196854)
72. Limaye A P., Corey L, Koelle D M., Davis C L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000 356 9230 645-649 (Pubitemid 30627592)
73. Kruger R M., Shannon W D., Arens M Q., Lynch J P., Storch G A., Trulock E P. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999 68 9 1272-1279
74. Alain S, Honderlick P, Grenet D et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997 63 10 1533-1536 (Pubitemid 27237467)
75. Baldanti F, Simoncini L, Sarasini A et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998 66 3 324-329 (Pubitemid 28390213)
76. Lurain N S., Ammons H C., Kapell K S., Yeldandi V V., Garrity E R., O'Keefe J P. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996 62 4 497-502 (Pubitemid 26295825)
77. Mylonakis E, Kallas W M., Fishman J A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002 34 10 1337-1341 (Pubitemid 34507943)
78. Chou S, Marousek G, Guentzel S et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997 176 3 786-789 (Pubitemid 27360552)
79. Waldman W J., Knight D A., Lurain N S. et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999 68 6 814-825 (Pubitemid 29468200)
80. Avery R K., Bolwell B J., Yen-Lieberman B et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004 34 12 1071-1075 (Pubitemid 40028840)
81. Avery R K., Mossad S B., Poggio E et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010 90 4 419-426
82. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009 9 5 1214-1222
83. Yoshikawa T. Significance of human herpesviruses to transplant recipients. Curr Opin Infect Dis 2003 16 6 601-606
84. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005 18 1 217-245 (Pubitemid 40170670)
85. Jacobs F, Knoop C, Brancart F et al, Brussels Heart and Lung Transplantation Group. Human herpesvirus-6 infection after lung and heart-lung transplantation: a prospective longitudinal study. Transplantation 2003 75 12 1996-2001 (Pubitemid 36793281)
86. Nash P J., Avery R K., Tang W H., Starling R C., Taege A J., Yamani M H. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004 4 7 1200-1203 (Pubitemid 38868616)
87. Razonable R R., Rivero A, Brown R A. et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003 17 2 114-120 (Pubitemid 36833781)
88. Yoshida M, Yamada M, Tsukazaki T et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998 40 1-2 73-84 (Pubitemid 28535173)
89. Ross D J., Chan R CK, Kubak B, Laks H, Nichols W S. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation. Transplant Proc 2001 33 4 2603-2606 (Pubitemid 32830232)
90. Manuel O, Kumar D, Moussa G et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009 87 5 719-725
91. Brennan D C., Storch G A., Singer G G., Lee L, Rueda J, Schnitzler M A. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis 2000 181 5 1557-1561 (Pubitemid 30387744)
92. Wang F Z., Dahl H, Linde A, Brytting M, Ehrnst A, Ljungman P. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood 1996 88 9 3615-3620 (Pubitemid 26365600)
93. Collart F, Kerbaul F, Damaj G et al. Visceral Kaposi's sarcoma associated with human herpesvirus 8 seroconversion in a heart transplant recipient. Transplant Proc 2004 36 10 3173-3174 (Pubitemid 41126768)
94. Huang P M., Chang Y L., Chen J S. et al. Human herpesvirus-8 associated Kaposi's sarcoma after lung transplantation: a case report. Transplant Proc 2003 35 1 447-449
95. Preiksaitis J K., Cockfield S M. Epstein-Barr virus and lymphoproliferative disease after hematopoietic stem cell or solid organ transplantation. In: Bowden R A. Ljungman P Paya C V. eds. Transplant Infections. 2nd ed. Philadelphia, PA Lippincott-Williams and Wilkens 2003 326-349
96. Gottschalk S, Rooney C M., Heslop H E. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 56 29-44 (Pubitemid 40299772)
97. Preiksaitis J K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004 39 7 1016-1023 (Pubitemid 39313460)
98. Moss D J., Burrows S R., Silins S L., Misko I, Khanna R. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001 356 1408 475-488 (Pubitemid 32442747)
99. Rowe D T., Webber S, Schauer E M., Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001 3 2 79-87 (Pubitemid 32452922)
100. Gärtner B C., Fischinger J, Schäfer H, Einsele H, Roemer K, Müller-Lantzsch N. Epstein-Barr viral load as a tool to diagnose and monitor post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002 159 49-54
101. Schäfer H, Berger C, Aepinus C et al. Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation 2001 72 3 492-496 (Pubitemid 32769637)
102. Reams B D., McAdams H P., Howell D N., Steele M P., Davis R D., Palmer S M. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003 124 4 1242-1249 (Pubitemid 37290032)
103. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991 23 1 Pt 2 1101-1103
104. Cockfield S M., Preiksaitis J K., Jewell L D., Parfrey N A. Post-transplant lymphoproliferative disorder in renal allograft recipients: clinical experience and risk factor analysis in a single center. Transplantation 1993 56 1 88-96 (Pubitemid 23220578)
105. Walker R C., Marshall W F., Strickler J G. et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995 20 5 1346-1353
106. Swinnen L J., Costanzo-Nordin M R., Fisher S G. et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990 323 25 1723-1728
107. Libertiny G, Watson C J., Gray D W., Welsh K I., Morris P J. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001 88 10 1330-1334 (Pubitemid 32955411)
108. Dotti G, Fiocchi R, Motta T et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999 13 5 664-670 (Pubitemid 29243615)
109. Kapelushnik J, Ariad S, Benharroch D et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001 113 2 425-428 (Pubitemid 32523148)
110. McLaughlin K, Wajstaub S, Marotta P et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000 6 5 570-574
111. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993 342 88868887 1514-1516 (Pubitemid 23362168)
112. Funch D P., Brady J, Ko H H., Dreyer N A., Walker A M. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 2002 159 81-88
113. Ghobrial I M., Habermann T M., Macon W R. et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005 79 2 244-247
114. Harris N L., Ferry J A., Swerdlow S H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997 14 1 8-14 (Pubitemid 27078881)
115. Harris N L., Swerdlow S H., Frizerra G et al. Posttransplant lymphoproliferative disorders. In: Jaffe E S. Harris N L. Stein H Vardiman J W. eds. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tumours: WHO Classification of Tumours. Lyons, France IARC Press 2001 264-269
116. Gulley M L., Swinnen L J., Plaisance K T. Jr, Schnell C, Grogan T M., Schneider B G., Southwest Oncology Group. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003 76 6 959-964 (Pubitemid 37186027)
117. Nelson B P., Nalesnik M A., Bahler D W., Locker J, Fung J J., Swerdlow S H. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000 24 3 375-385 (Pubitemid 30127473)
118. Green M, Cacciarelli T V., Mazariegos G V. et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998 66 12 1641-1644 (Pubitemid 29034984)
119. Straathof K C., Savoldo B, Heslop H E., Rooney C M. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002 118 3 728-740 (Pubitemid 35007376)
120. Leung E, Shenton B K., Green K et al. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler. Transpl Infect Dis 2004 6 4 156-164 (Pubitemid 40516683)
121. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999 96 18 10391-10396 (Pubitemid 29422568)
122. Davis C L. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001 3 2 108-118 (Pubitemid 32452926)
123. Paya C V., Fung J J., Nalesnik M A. et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999 68 1517-1525
124. Gross T G. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res 2002 159 96-103
125. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000 11 Suppl 1 113-116
126. Ghobrial I M., Habermann T M., Ristow K M. et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005 46 2 191-196 (Pubitemid 40185948)
127. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001 345 13 1000
128. Leblond V, Dhedin N, Mamzer Bruneel M F. et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001 19 3 772-778 (Pubitemid 32119092)
129. Manuel O, Kumar D, Singer L G., Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008 27 1 11-16
130. Fuks L, Shitrit D, Fox B D. et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg 2009 87 2 423-426
131. Corey L, Spear P G. Infections with herpes simplex viruses (1). N Engl J Med 1986 314 11 686-691
132. Dummer J S., Armstrong J, Somers J et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 1987 155 2 202-206 (Pubitemid 17022858)
133. Holland H K., Wingard J R., Saral R. Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies. Cancer Invest 1990 8 5 509-521
134. Singh N, Dummer J S., Kusne S et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988 158 1 124-131
135. Smyth R L., Higenbottam T W., Scott J P. et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 1990 49 4 735-739 (Pubitemid 20146955)
136. Taylor R J., Saul S H., Dowling J N., Hakala T R., Peel R L., Ho M. Primary disseminated herpes simplex infection with fulminant hepatitis following renal transplantation. Arch Intern Med 1981 141 11 1519-1521 (Pubitemid 11008153)
137. Lakeman F D., Whitley R J., National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. J Infect Dis 1995 171 4 857-863
138. Gnann J W. Jr. Herpes simplex and Varicella Zoster infection after hemopoietic stem cell or solid organ transplantation. In: Bowden R A. Ljungman P Paya C V. eds. Transplant Infections. 2nd ed. Philadelphia Lippincott-Williams and Wilkens 2003 350-366
139. Perry C M., Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996 52 5 754-772 (Pubitemid 26382191)
140. Gäbel H, Flamholc L, Ahlfors K. Herpes simplex virus hepatitis in a renal transplant recipient: successful treatment with acyclovir. Scand J Infect Dis 1988 20 4 435-438
141. Gnann J W. Jr, Whitley R J. Clinical practice: herpes zoster. N Engl J Med 2002 347 5 340-346
142. Locksley R M., Flournoy N, Sullivan K M., Meyers J D. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985 152 6 1172-1181 (Pubitemid 16215593)
143. Liesegang T J. Varicella zoster viral disease. Mayo Clin Proc 1999 74 10 983-998 (Pubitemid 29471194)
144. Zaia J A., Levin M J., Preblud S R. et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983 147 4 737-743 (Pubitemid 13088249)
145. Broyer M, Tete M J., Guest G, Gagnadoux M F., Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997 99 1 35-39 (Pubitemid 27136599)